Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who have been formally diagnosed with severe asthma, as defined by the Canadian Thoracic Society guidelines.
- People whose treating doctor has determined them to be eligible for treatment with mepolizumab.
- People who are able to understand and willing to sign the consent form for the trial.
Who may not be able to join:
- People who have a lung or breathing condition other than asthma.
- People who have certain other conditions that could affect the results of the study, such as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (conditions that involve abnormal levels of certain immune cells affecting multiple organs).
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andréanne Côté, MD, IUCPQ-UL
Phone: 4186568711
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of eosinophilic vs non-eosinophilic remaining exacerbation during the treatment period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.